[Acute lymphoblastic leukemia: a genomic perspective].

Area of Science:

• Genomics
• Oncology
• Pharmacogenomics

Background:

• Genomic sequencing technologies offer insights into human genome structure and clinical applications.
• Acute lymphoblastic leukemia (ALL) is a common pediatric cancer where genomic data can improve patient management.

Purpose of the Study:

• To review the genomic landscape of ALL.
• To highlight genomic strategies for identifying clinical biomarkers.
• To discuss the potential for personalized therapeutic schemes in ALL.

Main Methods:

• Review of current genomic technologies and their application in ALL.
• Identification of specific genetic variations, such as single nucleotide polymorphisms (SNPs).
• Analysis of gene variants impacting drug metabolism and toxicity.

Main Results:

• Genomic tools can detect patients at high risk of relapse (minimal residual disease).
• Genetic profiling identifies individuals susceptible to adverse chemotherapy reactions.
• TPMT gene variations necessitate significant mercaptopurine dose reduction to prevent toxicity.

Conclusions:

• Genomic approaches are crucial for risk stratification and personalized treatment in ALL.
• Biomarker discovery through genomics enhances patient-tailored therapeutic strategies.
• Pharmacogenomic insights, like TPMT genotyping, are vital for safe and effective ALL treatment.